Embecta Corporation (EMBC)

EMBC Investment Deadline: Embecta Securities Fraud Class Action Focuses on Insulin Pen Issues; Investors Notified of August 17 Court DeadlineJuly 7, 2026 6:37 AM
PR Newswire (US) A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.NEW YORK, July 7, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.Key Details of the Embecta ($EMBC) Class Action:Lead Plaintiff Deadline: August 17, 2026Alleged Misconduct: Securities fraud relating to Embecta's statements about the strength of its insulin pen needle product category.Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock DropCourt: U.S. District Court for the District of New JerseyAction: Contact BFA Law to discuss your rightsInvestors have until August 17, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Apitz-Grossman v. Embecta Corp., et al., No. 26-cv-07217.Why is Embecta Being Sued for Securities Fraud? Embecta is a medical device company that produces insulin pens for patients with diabetes. According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that "prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio."As alleged, in truth, Embecta faced significant competition and "overall market softness for insulin pens and pen needles."Why did Embecta's Stock Drop?On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer. Embecta also reported an "overall market volume softness for insulin pens and pen needles in the retail channel," admitting that "we have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported." As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share.This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. Click here for more information: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.What Can You Do?If you invested in Embecta, you may have legal options and are encouraged to submit your information to the firm.All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.Submit your information by visiting:https://www.bfalaw.com/cases/embecta-class-action-lawsuitWhy Bleichmar Fonti & Auld LLP?BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space."  One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.For more information about BFA and its attorneys, please visit https://www.bfalaw.com.https://www.bfalaw.com/cases/embecta-class-action-lawsuitAttorney advertising. Past results do not guarantee future outcomes. View original content to download multimedia:https://www.prnewswire.com/news-releases/embc-investment-deadline-embecta-securities-fraud-class-action-focuses-on-insulin-pen-issues-investors-notified-of-august-17-court-deadline-302819045.htmlSOURCE Bleichmar Fonti & Auld LLP Original: EMBC Investment Deadline: Embecta Securities Fraud Class Action Focuses on Insulin Pen Issues; Investors Notified of August 17 Court Deadline

Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBCJune 29, 2026 4:58 AM
PR Newswire (US) LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 25, 2025 to May 4, 2026DEADLINE: August 17, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Embecta was aware of challenges in the pen needle market, but still led investors to believe its fiscal guidance was based on reliable data. Based on these facts, Embecta's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com View original content:https://www.prnewswire.com/news-releases/embecta-corp-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--embc-302812969.htmlSOURCE DJS Law Group LLP Original: Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC

EMBC Breaking Class Action Lawsuit: Embecta Sued for Securities Fraud after Insulin Pen Issues Lead to 57% Stock Drop – Investors Notified to Contact BFA LawJune 23, 2026 5:13 PM
Business Wire A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit. Key Details of the Embecta ($EMBC) Class Action: Lead Plaintiff Deadline: August 17, 2026 Alleged Misconduct: Securities fraud relating to Embecta’s statements about the strength of its insulin pen needle product category. Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop Court: U.S. District Court for the District of New Jersey Action: Contact BFA Law to discuss your rights Investors have until August 17, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Apitz-Grossman v. Embecta Corp., et al., No. 26-cv-07217. Why is Embecta Being Sued for Securities Fraud? Embecta is a medical device company that produces insulin pens for patients with diabetes. According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that “prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio.” As alleged, in truth, Embecta faced significant competition and “overall market softness for insulin pens and pen needles.” Why did Embecta’s Stock Drop? On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer. Embecta also reported an “overall market volume softness for insulin pens and pen needles in the retail channel,” admitting that “we have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported.” As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share. This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. Click here for more information: https://www.bfalaw.com/cases/embecta-class-action-lawsuit. What Can You Do? If you invested in Embecta, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.” Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit https://www.bfalaw.com. https://www.bfalaw.com/cases/embecta-class-action-lawsuit Attorney advertising. Past results do not guarantee future outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20260623430798/en/ Adam McCall
adam@bfalaw.com
212.789.3619 Original: EMBC Breaking Class Action Lawsuit: Embecta Sued for Securities Fraud after Insulin Pen Issues Lead to 57% Stock Drop – Investors Notified to Contact BFA Law

Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – EMBCJune 18, 2026 10:36 AM
Business WireThe DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 25, 2025 to May 4, 2026DEADLINE: August 17, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Embecta was aware of challenges in the pen needle market, but still led investors to believe its fiscal guidance was based on reliable data. Based on these facts, Embecta’s public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.View source version on businesswire.com: https://www.businesswire.com/news/home/20260618102519/en/David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com Original: Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – EMBC

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600June 5, 2026 7:25 PM
PR Newswire (US) NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026S&P 500AdditionMarvell TechnologyMRVLInformation TechnologyJune 22, 2026S&P 500DeletionPool CorpPOOLConsumer DiscretionaryJune 22, 2026S&P 500AdditionFlexFLEXInformation TechnologyJune 22, 2026S&P 500DeletionThe Campbell's CompanyCPBConsumer StaplesJune 22, 2026S&P MidCap 400AdditionRokuROKUCommunication ServicesJune 22, 2026S&P MidCap 400DeletionFlex FLEXInformation TechnologyJune 22, 2026S&P MidCap 400AdditionCoeur MiningCDEMaterialsJune 22, 2026S&P MidCap 400DeletionBellRing Brands BRBRConsumer StaplesJune 22, 2026S&P MidCap 400AdditionSemtechSMTCInformation TechnologyJune 22, 2026S&P MidCap 400DeletionCotyCOTYConsumer StaplesJune 22, 2026S&P MidCap 400AdditionSanminaSANMInformation TechnologyJune 22, 2026S&P MidCap 400DeletionConcentrix CNXCIndustrialsJune 22, 2026S&P MidCap 400AdditionViavi Solutions VIAVInformation TechnologyJune 22, 2026S&P MidCap 400DeletionBlackbaud BLKBInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionPoolPOOLConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionEmbecta EMBCHealth CareJune 22, 2026S&P SmallCap 600AdditionThe Campbell's CompanyCPBConsumer StaplesJune 22, 2026S&P SmallCap 600DeletionUniversal Health Realty Trust UHTReal EstateJune 22, 2026S&P SmallCap 600AdditionCotyCOTYConsumer StaplesJune 22, 2026S&P SmallCap 600DeletionSemtechSMTCInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionConcentrix CNXCIndustrialsJune 22, 2026S&P SmallCap 600DeletionSanmina SANMInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionBlackbaudBLKBInformation TechnologyJune 22, 2026S&P SmallCap 600DeletionViavi SolutionsVIAVInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionCredit Acceptance CACCFinancialsJune 22, 2026S&P SmallCap 600DeletionOxford IndustriesOXMConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionLazardLAZFinancialsJune 22, 2026S&P SmallCap 600DeletionGogoGOGOCommunication ServicesJune 22, 2026S&P SmallCap 600AdditionEastern BanksharesEBCFinancialsJune 22, 2026S&P SmallCap 600DeletionPRA GroupPRAAFinancialsJune 22, 2026S&P SmallCap 600AdditionWesbancoWSBCFinancialsJune 22, 2026S&P SmallCap 600DeletionInsteel IndustriesIIINIndustrialsJune 22, 2026S&P SmallCap 600AdditionWarby ParkerWRBYConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionEthan Allen InteriorsETDConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionNicolet BanksharesNICFinancialsJune 22, 2026S&P SmallCap 600DeletionCytek BiosciencesCTKBHealth CareJune 22, 2026S&P SmallCap 600AdditionLiquidia LQDAHealth CareJune 22, 2026S&P SmallCap 600DeletionMonroMNROConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionRush Street InteractiveRSIConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionVital FarmsVITLConsumer StaplesJune 22, 2026S&P SmallCap 600AdditionUnited States Lime & MineralsUSLMMaterialsJune 22, 2026S&P SmallCap 600DeletionCable OneCABOCommunication ServicesJune 22, 2026S&P SmallCap 600AdditionInvenTrust PropertiesIVTReal EstateJune 22, 2026S&P SmallCap 600DeletionForward AirFWRDIndustrialsABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com View original content:https://www.prnewswire.com/news-releases/marvell-technology-and-flex-set-to-join-sp-500-others-to-join-sp-midcap-400-and-sp-smallcap-600-302793159.htmlSOURCE S&P Dow Jones Indices Original: Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

$EMBC: Spun-off from BectonDickenson.... now $30.20


Could come even lower to sub $15 and then I'll consider a stake in this


https://finance.yahoo.com/news/bd-announces-completion-embecta-corp-105000224.html


Here is the most current Investor DECK........


https://investors.embecta.com/static-files/cbb07e14-b84a-4c10-a6a8-219014e2a5d4


GO $EMBC